How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levofloxacin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Levaquin — Competitive Intelligence Brief

Levaquin (levofloxacin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone Antibacterial [EPC]. Area: Infectious Disease.

marketed Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Levaquin (levofloxacin) — Generic (originally Daiichi Sankyo/J&J). Levofloxacin is a fluoroquinolone antibacterial agent.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levaquin TARGET	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	marketed	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Baxdela	DELAFLOXACIN	Melinta	marketed	Fluoroquinolone Antibacterial		2017-01-01
Levaquin	Levofloxacin	Santen	marketed	Fluoroquinolone Antibacterial [EPC]	Multidrug and toxin extrusion protein 1	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone Antibacterial [EPC] class)

Generic (originally Daiichi Sankyo/J&J) · 1 drug in this class
Santen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levaquin — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab